​

Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMNM Stock Forecast

Immunome (IMNM) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $34.50, with a high of $40.00 and a low of $26.00. This represents a 35.67% increase from the last price of $25.43.

$10 $16 $22 $28 $34 $40 High: $40 Avg: $34.5 Low: $26 Last Closed Price: $25.43

IMNM Stock Rating

Immunome stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

IMNM Price Target Upside V Benchmarks

TypeNameUpside
StockImmunome35.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-57
Avg Price Target-$36.20$32.14
Last Closing Price$25.43$25.43$25.43
Upside/Downside-42.35%26.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26211---13
Dec, 25210---12
Nov, 25210---12
Oct, 25210---12
Sep, 2528---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 16, 2025Lake Street$32.00$23.3936.81%25.84%
Dec 16, 2025Evercore ISI$40.00$23.3571.31%57.29%
Dec 15, 2025Leerink Partners$40.00$22.6576.60%57.29%
Dec 01, 2025Karina RabayevaTruist Financial$36.00$18.4295.44%41.57%
Nov 17, 2025Stephens$33.00$17.1492.53%29.77%
Sep 05, 2025Craig-Hallum$26.00$10.52147.15%2.24%
Aug 22, 2025Evercore ISI$18.00$10.3074.76%-29.22%
Aug 13, 2024Biren AminPiper Sandler$23.00$12.6481.96%-9.56%
Apr 15, 2024Michael SchmidtGuggenheim$35.00$20.5870.07%37.63%
Apr 01, 2024David NierengartenWedbush$33.00$24.6833.71%29.77%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 16, 2025Lake StreetBuyBuyhold
Dec 16, 2025Evercore ISIOutperformOutperformhold
Dec 16, 2025GuggenheimBuyBuyhold
Sep 22, 2025Goldman SachsBuyinitialise
Sep 05, 2025Craig-HallumBuyinitialise
Aug 22, 2025Evercore ISIOutperforminitialise
Nov 14, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.38$-5.00----
Avg Forecast$-0.92$-4.42$-3.11$-3.21$-2.81$-1.32
High Forecast$-0.47$-4.32$-2.48$-2.36$-1.72$-1.01
Low Forecast$-1.19$-4.56$-4.10$-4.36$-3.97$-1.63
Surprise %484.78%13.12%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$14.02M$9.04M----
Avg Forecast$12.27M$9.41M$3.15M$17.90M$76.14M$223.12M
High Forecast$14.02M$11.40M$3.71M$17.90M$76.14M$262.84M
Low Forecast$10.50M$7.56M$2.58M$17.90M$76.14M$183.11M
Surprise %14.28%-3.89%----

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-106.81M$-292.96M----
Avg Forecast$-16.47M$-88.13M$-65.26M$-66.63M$-56.45M$-26.19M
High Forecast$-9.41M$-85.78M$-49.16M$-46.75M$-34.13M$-20.09M
Low Forecast$-23.53M$-90.47M$-81.35M$-86.51M$-78.77M$-32.26M
Surprise %548.56%232.44%----

IMNM Forecast FAQ

Is Immunome stock a buy?

Immunome stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunome is a favorable investment for most analysts.

What is Immunome's price target?

Immunome's price target, set by 9 Wall Street analysts, averages $34.5 over the next 12 months. The price target range spans from $26 at the low end to $40 at the high end, suggesting a potential 35.67% change from the previous closing price of $25.43.

How does Immunome stock forecast compare to its benchmarks?

Immunome's stock forecast shows a 35.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immunome over the past three months?

  • January 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immunome’s EPS forecast?

Immunome's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.11, marking a -37.80% decrease from the reported $-5 in 2024. Estimates for the following years are $-3.21 in 2026, $-2.81 in 2027, and $-1.32 in 2028.

What is Immunome’s revenue forecast?

Immunome's average annual revenue forecast for its fiscal year ending in December 2025 is $3.15M, reflecting a -65.18% decrease from the reported $9.04M in 2024. The forecast for 2026 is $17.9M, followed by $76.14M for 2027, and $223.12M for 2028.

What is Immunome’s net income forecast?

Immunome's net income forecast for the fiscal year ending in December 2025 stands at $-65.257M, representing a -77.73% decrease from the reported $-293M in 2024. Projections indicate $-66.63M in 2026, $-56.449M in 2027, and $-26.194M in 2028.